Literature DB >> 35059585

De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.

Umar Wazir1,2, Kefah Mokbel1.   

Abstract

Breast cancer treatment has seen many advances in recent decades, lessening the morbidity to patients, while improving outcomes. Central to these gains has been the introduction of breast conserving surgery and neoadjuvant systemic therapy (NST). There is a considerable interest in further de-escalation of the treatment of breast cancer, which is being studied in several ongoing randomised trials. We aimed to appraise the current literature regarding the various aspects of de-escalation of surgical treatment of breast cancer after NST, and attempt to prognosticate the future course of breast oncotherapy. ©Copyright 2022 by Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  Breast cancer; de-escalation; neo-adjuvant therapy

Year:  2021        PMID： 35059585      PMCID： PMC8734515          DOI： 10.4274/ejbh.galenos.2021.2021-5-4

Source DB:  PubMed          Journal:  Eur J Breast Health


  40 in total

1.  Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.

Authors:  Sarah S Mougalian; Pamela R Soulos; Brigid K Killelea; Donald R Lannin; Maysa M Abu-Khalaf; Michael P DiGiovanna; Tara B Sanft; Lajos Pusztai; Cary P Gross; Anees B Chagpar
Journal:  Cancer       Date:  2015-04-22       Impact factor: 6.860

2.  Fine-tuning chemotherapy in the era of dual HER2 targeting.

Authors:  Sherene Loi
Journal:  Lancet Oncol       Date:  2018-11-06       Impact factor: 41.316

3.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

4.  Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.

Authors:  Jean-Marc Classe; Cecile Loaec; P Gimbergues; S Alran; C Tunon de Lara; P F Dupre; Roman Rouzier; C Faure; N Paillocher; M P Chauvet; G Houvenaeghel; M Gutowski; P De Blay; J L Verhaeghe; E Barranger; C Lefebvre; C Ngo; G Ferron; C Palpacuer; L Campion
Journal:  Breast Cancer Res Treat       Date:  2018-10-20       Impact factor: 4.872

5.  Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database.

Authors:  Catherine Tsai; Beiqun Zhao; Theresa Chan; Sarah L Blair
Journal:  Am J Surg       Date:  2019-11-11       Impact factor: 2.565

6.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079

Review 7.  The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.

Authors:  Chong Geng; Xiao Chen; Xiaohua Pan; Jiyu Li
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

8.  Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.

Authors:  Seho Park; Jung Hyun Yoon; Joohyuk Sohn; Hyung Seok Park; Hee Jung Moon; Min Jung Kim; Eun-Kyung Kim; Seung Il Kim; Byeong-Woo Park
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

Review 9.  Neoadjuvant immunotherapy in breast cancer: a paradigm shift?

Authors:  Elena Fountzila; Michail Ignatiadis
Journal:  Ecancermedicalscience       Date:  2020-12-03

Review 10.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Authors: 
Journal:  Lancet Oncol       Date:  2017-12-11       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.